This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Liposomal Doxorubicin Market

Market Insights on Liposomal Doxorubicin covering sales outlook, demand forecast & up-to-date key trends

Liposomal Doxorubicin Market by Product, Application & Region - Forecast 2022 - 2032

Liposomal Doxorubicin Market Outlook (2022-2032)

[315 Pages Report] The liposomal doxorubicin market is predicted to register a promising CAGR of 5.4% during 2022-2032. 

The lead mining software market is anticipated to reach US$ 2.1 Bn by 2032 from US$ 1,240 Mn in 2022.

“The development of revolutionary nanodrugs and enhanced chemotherapeutic medicines, among others, is anticipated to fuel the liposomal doxorubicin market growth.”

The sales of liposomal doxorubicin drugs are rising due to the change in the working population's sedentary lifestyles and stressful schedules, which is increasing the frequency of these diseases and favourably boosting the liposomal doxorubicin market growth.

Attributes

Details

Liposomal Doxorubicin Market CAGR (2022-2032)

5.4%

Liposomal Doxorubicin Market Value (2022)

US$ 1,240 Mn

Liposomal Doxorubicin Market Value (2032)

US$ 2.1 Bn

Customize this Report

Let us know your requirement to get
100% FREE customization

What is the COVID-19 Impact on the Liposomal Doxorubicin Market?

COVID-19 has had a global influence on every aspect of the healthcare industry, including the liposomal doxorubicin market, with severe disruptions to businesses and economic activity around the world.

The sales of liposomal doxorubicin were greatly affected as the COVID-19 pandemic caused havoc on healthcare systems around the world, causing routine care to be disrupted in many hospitals and exposing cancer patients to substantial dangers.

In 2021, researchers published a study titled "Impact of COVID-19 on cancer care in India: a cohort study," in which they collected data on new patient registrations, outpatient clinic visits, hospital admissions, daycare admissions for chemotherapy, minor and major surgeries, patients receiving radiotherapy, and diagnostic tests. 

The researchers also found that the number of new patients registered decreased from 112 270 to 51 760. The data suggests that the demand for liposomal doxorubicin decreased due to COVID-19.

The sales of liposomal doxorubicin also decreased as the patient's follow-up visits, hospital admissions, and outpatient chemotherapy was reduced due to COVID-19. As a result, COVID-19 had a substantial impact on the liposomal doxorubicin market.

As the COVID-19 situation gets under control, the demand for liposomal doxorubicin drugs is likely to witness massive growth.

What are the Key Dynamics Governing the Growth of the Liposomal Doxorubicin Market?

The demand for liposomal doxorubicin is high as it is a medicine used to treat cancer, Kaposi Sarcoma, and a variety of other diseases. The global liposomal doxorubicin market share is expected to grow due to rising cancer incidence, the development of technologically sophisticated drug delivery methods, increased patient awareness, and rising disposable incomes.

Following the failure of prior systemic chemotherapy for ovarian cancer and AIDS-related Kaposi's sarcoma, the sales of liposomal doxorubicin are expected to rise dramatically. Another factor driving the demand for liposomal doxorubicin is the rising number of cases of hepatocellular carcinoma and rising survival rates.

The liposomal doxorubicin market size is growing as people become more aware of the various cancer treatment options available. Innovations enable site-specific drug delivery and regulated drug release in the body.

Other factors expected to fuel the sales of liposomal doxorubicin include considerable improvements in healthcare infrastructure, particularly in developing economies, as well as extensive research and development (R&D) initiatives in the field of oncology.

The FDA approved a generic version of liposomal doxorubicin formulation for second-line treatment of ovarian cancer and chemotherapy routine for various cancers to address the lack of branded liposomal doxorubicin, such as Doxil or Caelyx. This factor had a significant impact on the sales of liposomal doxorubicin.

In addition, in the United States, which is the largest market for liposomal doxorubicin formulation, the import of the medicine was permitted under "exercise enforcement discretion." The rising demand for liposomal doxorubicin has resulted in a significant increase in the importation of doxorubicin HCl liposome injections, which is projected to propel the liposomal doxorubicin market size forward.

Several government programs aimed at raising awareness and providing new cancer therapy methods have boosted the demand for liposomal doxorubicin and are likely to do so during the forecast period.

For example, in 2020, the National Comprehensive Cancer Control Program, which provides funding, guidance, and technical assistance to help programs implement cancer prevention and control plans, may increase the market opportunities for key players to launch new products into the market, boosting the sales of liposomal doxorubicin.

Thus, the liposomal doxorubicin market is predicted to develop greatly as a result of the variables indicated above; nevertheless, adverse effects related to liposomal doxorubicin are expected to limit liposomal doxorubicin market growth.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Comparative View of Adjacent Liposomal Doxorubicin Market

Liposomal Doxorubicin Market:

Attributes

Liposomal Doxorubicin Market

CAGR (2022 - 2032)

5.4%

Market Value (2026)

US$ 1.53 Bn

Growth Factor

Rising cancer incidence, the development of technologically sophisticated drug delivery methods, and increased patient awareness

Opportunity

Funding, guidance, and technical assistance to help programs implement cancer prevention and control plans, may increase the market opportunities for key players.

Key Trends

The development of archetypal nanodrugs and better chemotherapeutic medicines.

Cancer Therapy Market:

Attributes

Cancer Therapy Market

CAGR (2022 - 2032)

9%

Market Value (2026)

US$ 268 Bn

Growth Factor

The rising number of cancer cases is predicted to increase the demand for sophisticated cancer medicines in order to treat patients effectively.

Opportunity

Increasing cancer prevalence worldwide, increasing patient assistance programs (PAPs), increasing government activities for cancer awareness.

Key Trends

Significant businesses'  R&D initiatives, as well as the growing demand for personalized medicine are some of the key trends.

Oncology drugs market:

Attributes

Oncology drugs market

CAGR (2022 - 2032)

7.5%

Market Value (2026)

US$ 208.35 Bn

Growth Factor

The growth of the oncology drugs market is aided by increased cancer awareness and early cancer screening.

Opportunity

Emerging economies' great potential and the large number of prospective pharmaceuticals in the pipeline are projected to provide lucrative opportunities.

Key Trends

Advance therapies (biological and targeted medication therapies) are becoming more popular, and the global geriatric population is growing.

One of the primary factors driving the growth of the global liposomal doxorubicin market share is the dramatic increase in cancer cases around the world. The sales of liposomal doxorubicin are expected to be driven by key factors such as a hectic lifestyle and bad eating habits that result in a variety of health issues over the projected period.

During the forecast period, innovations and research and development initiatives are expected to provide new growth prospects for market players. Furthermore, the expansion of healthcare infrastructure is expected to boost the demand for liposomal doxorubicin in the near future.

Some of the drivers expected to propel the liposomal doxorubicin market size in the coming years are increased use of chemotherapy treatments, rising demand for targeted therapy drugs, and increased investment by private firms to cater to this application.

Another key reason likely to boost liposomal doxorubicin market growth in the near future is the increasing number of doxorubicin applications.

What is the Segmentation Outlook for the Liposomal Doxorubicin Market?

Global Study on liposomal doxorubicin market categorized the market by product and application. This category is further divided into small segments that expand their channels in multiple market spaces. These segments perform differently in multiple markets as they have a stronghold in multiple regions.

The product category is segmented into J7J (Doxil/Caelyx), Sun Pharma (Lipodox), and Teva (Myocet), while the application category is segmented into leukemia, bone sarcoma, breast cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, Kaposi sarcoma, other applications.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Which Segment is likely to Lead the Liposomal Doxorubicin Market by Product Type?

By product type, liposomal doxorubicin market analysis finds that the lipobox segment is the biggest segment and is expected to hold the major chunk of the market in the forecast period, thriving at a CAGR of 4.9%.

The factors behind the sales of this segment are its high consumption, expanded supply chain and availability of its distribution channels, along with increasing manufacturing units around the world. Growing chronic diseases like liver and kidney cancer are also expanding the liposomal doxorubicin market size.

Which Segment is likely to Lead the Liposomal Doxorubicin Market by Application?

By application, the liver cancer segment consumes most of the liposomal doxorubicin market, which thrives on a CAGR of 4.8% between 2022 and 2032. Factors driving the high sales of this segment are the greater easy availability, high use of the drug in the treatment of liver cancer, high success rate and rising effective use.

Liver cancer is also a growing cancer type amongst men and women, increasing the high health effects. Liposomal doxorubicin helps in the treatment and allows doctors to have better control over its quantity.

What is the Regional Analysis for the Liposomal doxorubicin Market?

Liposomal doxorubicin market report explains that the market is divided into regions; North America, Latin America, Asia Pacific, Middle East and Africa (MEA) and Europe. The biggest market is the United States, which is growing at an average CAGR of 5.2% between 2022-2032.

The region is expected to hold a market revenue of US$ 743 Mn by the end of 2032. The factors behind the high sales of liposomal doxorubicin are increasing cancer patients and the use of advanced drugs on them.

Apart from this, China is the second highest growing market for liposomal doxorubicin market, thriving at a CAGR of 4.8% and will hold the second-highest value of US$ 150 Mn by 2032, while the Japan region is growing with a CAGR of 3.8% between 2022-2032, generating a revenue of US$ 121.2 Mn. The UK also grows along with Japan the forecasted value of US$ 87 Mn (2032) at a CAGR of 4.5% between 2022-2032.

Regions

CAGR (2022-2032)

United States

5.2%

United Kingdom

4.5%

China

4.8%

Japan

3.8%

South Korea

3.0%

  • United States hold the biggest portion in the liposomal doxorubicin market.
  • US is the highest growing market followed by China in the making the Asia Pacific and North America region the fastest growing region, thriving at a CAGR of 5.2% and 4.8% respectfully between 2022 and 2032.
  • Unhealthy lifestyle and increasing obesity is converting into rising cancer patients in North American countries like US and Canada, expanding the liposomal doxorubicin market size in the region.

How is the Competition in the Liposomal Doxorubicin Market?

The competitive landscape of liposomal doxorubicin market is a part of pharmaceutical industry that makes it dynamic and highly capital driven. Companies also collaborate and merge with other companies, which strengthens their roots and expands their distributional channels and manufacturing units.

Key Players

Recent Development in the Market

  • Pfizer has introduced its set of liposomal doxorubicin, including premierpro, novaplus, improving the drug quality by making it more efficient. This pushes the demand for liposomal doxorubicin in new regions.
  • Cipla Inc has launched its series of liposomal doxorubicin by products like shots and ONCODOX PEG injections, improving the sales of liposomal doxorubicin overall.

Key Segments

By Products:

  • J7J (Doxil/Caelyx)
  • Sun Pharma (Lipodox)
  • Teva (Myocet)

By Products:

  • Leukemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Liver Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Kaposi Sarcoma

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa (MEA)
  • Latin America

Frequently Asked Questions

The Liposomal doxorubicin market is set to grow at a CAGR of 5.4% through 2032.

US is the biggest region in the liposomal doxorubicin market with a CAGR of 5.2% between 2022 and 2032.

The lipodox segment is the leading product in the liposomal doxorubicin market.

The liposomal doxorubicin market is set to reach US$ 2.1 Bn by 2032.

North America has the highest growth potential in the liposomal doxorubicin market, where US has the highest growth rate of 5.2% through 2032.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Summary of Statistics

    1.3. Key Market Characteristics & Attributes

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

    3.1. Risk Assessment

        3.1.1. COVID-19 Crisis and Impact on Liposomal Doxorubicin

        3.1.2. COVID-19 Impact Benchmark with Previous Crisis

        3.1.3. Impact on Market Value (US$ Mn)

        3.1.4. Assessment by Key Countries

        3.1.5. Assessment by Key Market Segments

        3.1.6. Action Points and Recommendation for Suppliers

    3.2. Key Trends Impacting the Market

    3.3. Formulation and Product Development Trends

4. Market Background and Foundation Data Points

    4.1. Global Liposomal Doxorubicin Market (US$ Mn)

    4.2. Liposomal Doxorubicin Market Opportunity Assessment (US$ Mn)

        4.2.1. Total Available Market

        4.2.2. Serviceable Addressable Market

        4.2.3. Serviceable Obtainable Market

    4.3. Market Scenario Forecast

        4.3.1. Demand in optimistic Scenario

        4.3.2. Demand in Likely Scenario

        4.3.3. Demand in Conservative Scenario

    4.4. Investment Feasibility Analysis

        4.4.1. Investment in Established Markets

            4.4.1.1. In Short Term

            4.4.1.2. In Long Term

        4.4.2. Investment in Emerging Markets

            4.4.2.1. In Short Term

            4.4.2.2. In Long Term

    4.5. Forecast Factors - Relevance & Impact

        4.5.1. Top Companies Historical Growth

        4.5.2. Global Liposomal Doxorubicin Market Growth

        4.5.3. Anechoic Chamber Adoption Rate, By Country

    4.6. Market Dynamics

        4.6.1. Market Driving Factors and Impact Assessment

        4.6.2. Prominent Market Challenges and Impact Assessment

        4.6.3. Liposomal Doxorubicin Market Opportunities

        4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

    5.1. Manufacturers’ Focus on Low Penetration High Growth Markets

    5.2. Banking on with Segments High Incremental Opportunity

    5.3. Peer Benchmarking

6. Global Liposomal Doxorubicin Market Demand Analysis 2015-2021 and Forecast, 2022-2032

    6.1. Historical Market Analysis, 2015-2021

    6.2. Current and Future Market Projections, 2022-2032

    6.3. Y-o-Y Growth Trend Analysis

7. Global Liposomal Doxorubicin Market Value Analysis 2015-2021 and Forecast, 2022-2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032, By Product

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Product, 2015-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032

        8.3.1. J&J (Doxil/Caelyx)

        8.3.2. Sun Pharma (Lipodox)

        8.3.3. Teva (Myocet)

        8.3.4. Others

    8.4. Market Attractiveness Analysis By Product

9. Global Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032, By Application

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Application , 2015-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application , 2022-2032

        9.3.1. Leukemia

        9.3.2. Bone Sarcoma

        9.3.3. Breast Cancer

        9.3.4. Endometrial Cancer

        9.3.5. Gastric Cancer

        9.3.6. Liver Cancer

        9.3.7. Kidney Cancer

        9.3.8. Multiple Myeloma

        9.3.9. Ovarian Cancer

        9.3.10. Kaposi Sarcoma

        9.3.11. Other Applications

    9.4. Market Attractiveness Analysis By Application

10. Global Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032, By Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021

    10.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. Asia Pacific

        10.3.5. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032

    11.1. Introduction

    11.2. Pricing Analysis

    11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        11.4.1. By Country

            11.4.1.1. U.S.

            11.4.1.2. Canada

            11.4.1.3. Rest of North America

        11.4.2. By Product

        11.4.3. By Application

    11.5. Market Attractiveness Analysis

        11.5.1. By Country

        11.5.2. By Product

        11.5.3. By Application

12. Latin America Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032

    12.1. Introduction

    12.2. Pricing Analysis

    12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        12.4.1. By Country

            12.4.1.1. Brazil

            12.4.1.2. Mexico

            12.4.1.3. Rest of Latin America

        12.4.2. By Product

        12.4.3. By Application

    12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Product

        12.5.3. By Application

13. Europe Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032

    13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        13.4.1. By Country

            13.4.1.1. Germany

            13.4.1.2. France

            13.4.1.3. U.K.

            13.4.1.4. Italy

            13.4.1.5. Benelux

            13.4.1.6. Nordic Countries

            13.4.1.7. Rest of Europe

        13.4.2. By Product

        13.4.3. By Application

    13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Product

        13.5.3. By Application

14. Asia Pacific Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        14.4.1. By Country

            14.4.1.1. China

            14.4.1.2. Japan

            14.4.1.3. South Korea

            14.4.1.4. Rest of Asia Pacific

        14.4.2. By Product

        14.4.3. By Application

    14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Product

        14.5.3. By Application

15. Middle East and Africa Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    15.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032

        15.4.1. By Country

            15.4.1.1. GCC Countries

            15.4.1.2. South Africa

            15.4.1.3. Turkey

            15.4.1.4. Rest of Middle East and Africa

        15.4.2. By Product

        15.4.3. By Application

    15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Product

        15.5.3. By Application

16. Key Countries Liposomal Doxorubicin Market Analysis 2015-2021 and Forecast 2022-2032

    16.1. Introduction

        16.1.1. Market Value Proportion Analysis, By Key Countries

        16.1.2. Global Vs. Country Growth Comparison

    16.2. US Liposomal Doxorubicin Market Analysis

        16.2.1. Value Proportion Analysis by Market Taxonomy

        16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.2.2.1. By Product

            16.2.2.2. By Application

    16.3. Canada Liposomal Doxorubicin Market Analysis

        16.3.1. Value Proportion Analysis by Market Taxonomy

        16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.3.2.1. By Product

            16.3.2.2. By Application

    16.4. Mexico Liposomal Doxorubicin Market Analysis

        16.4.1. Value Proportion Analysis by Market Taxonomy

        16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.4.2.1. By Product

            16.4.2.2. By Application

    16.5. Brazil Liposomal Doxorubicin Market Analysis

        16.5.1. Value Proportion Analysis by Market Taxonomy

        16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.5.2.1. By Product

            16.5.2.2. By Application

    16.6. Germany Liposomal Doxorubicin Market Analysis

        16.6.1. Value Proportion Analysis by Market Taxonomy

        16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.6.2.1. By Product

            16.6.2.2. By Application

    16.7. France Liposomal Doxorubicin Market Analysis

        16.7.1. Value Proportion Analysis by Market Taxonomy

        16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.7.2.1. By Product

            16.7.2.2. By Application

    16.8. Italy Liposomal Doxorubicin Market Analysis

        16.8.1. Value Proportion Analysis by Market Taxonomy

        16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.8.2.1. By Product

            16.8.2.2. By Application

    16.9. BENELUX Liposomal Doxorubicin Market Analysis

        16.9.1. Value Proportion Analysis by Market Taxonomy

        16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.9.2.1. By Product

            16.9.2.2. By Application

    16.10. UK Liposomal Doxorubicin Market Analysis

        16.10.1. Value Proportion Analysis by Market Taxonomy

        16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.10.2.1. By Product

            16.10.2.2. By Application

    16.11. Nordic Countries Liposomal Doxorubicin Market Analysis

        16.11.1. Value Proportion Analysis by Market Taxonomy

        16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.11.2.1. By Product

            16.11.2.2. By Application

    16.12. China Liposomal Doxorubicin Market Analysis

        16.12.1. Value Proportion Analysis by Market Taxonomy

        16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.12.2.1. By Product

            16.12.2.2. By Application

    16.13. Japan Liposomal Doxorubicin Market Analysis

        16.13.1. Value Proportion Analysis by Market Taxonomy

        16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.13.2.1. By Product

            16.13.2.2. By Application

    16.14. South Korea Liposomal Doxorubicin Market Analysis

        16.14.1. Value Proportion Analysis by Market Taxonomy

        16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.14.2.1. By Product

            16.14.2.2. By Application

    16.15. GCC Countries Liposomal Doxorubicin Market Analysis

        16.15.1. Value Proportion Analysis by Market Taxonomy

        16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.15.2.1. By Product

            16.15.2.2. By Application

    16.16. South Africa Liposomal Doxorubicin Market Analysis

        16.16.1. Value Proportion Analysis by Market Taxonomy

        16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.16.2.1. By Product

            16.16.2.2. By Application

    16.17. Turkey Liposomal Doxorubicin Market Analysis

        16.17.1. Value Proportion Analysis by Market Taxonomy

        16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032

            16.17.2.1. By Product

            16.17.2.2. By Application

        16.17.3. Competition Landscape and Player Concentration in the Country

17. Market Structure Analysis

    17.1. Market Analysis by Tier of Companies

    17.2. Market Concentration

    17.3. Market Share Analysis of Top Players

    17.4. Market Presence Analysis

        17.4.1. By Regional footprint of Players

        17.4.2. Product footprint by Players

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Competition Deep Dive

        18.3.1. Pfizer Inc

            18.3.1.1. Overview

            18.3.1.2. Product Portfolio

            18.3.1.3. Sales Footprint

            18.3.1.4. Strategy Overview

        18.3.2. Sun Pharmaceutical Industries Ltd

            18.3.2.1. Overview

            18.3.2.2. Product Portfolio

            18.3.2.3. Sales Footprint

            18.3.2.4. Strategy Overview

        18.3.3. Cipla Inc

            18.3.3.1. Overview

            18.3.3.2. Product Portfolio

            18.3.3.3. Sales Footprint

            18.3.3.4. Strategy Overview

        18.3.4. Cadila Pharmaceuticals

            18.3.4.1. Overview

            18.3.4.2. Product Portfolio

            18.3.4.3. Sales Footprint

            18.3.4.4. Strategy Overview

        18.3.5. Teva Pharmaceuticals Industries Ltd

            18.3.5.1. Overview

            18.3.5.2. Product Portfolio

            18.3.5.3. Sales Footprint

            18.3.5.4. Strategy Overview

        18.3.6. Janssen Products LP

            18.3.6.1. Overview

            18.3.6.2. Product Portfolio

            18.3.6.3. Sales Footprint

            18.3.6.4. Strategy Overview

19. Assumptions and Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2015 – 2021

Table 2: Global Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2022 – 2032

Table 3: Global Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2015 – 2021

Table 4: Global Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2022 – 2032

Table 5: Global Liposomal Doxorubicin Market , By Region, 2015 – 2021

Table 6: Global Liposomal Doxorubicin Market , By Region, 2022 – 2032

Table 7: North America Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2015 – 2021

Table 8: North America Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2022 – 2032

Table 9: North America Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2015 – 2021

Table 10: North America Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2022 – 2032

Table 11: North America Liposomal Doxorubicin Market , By Country, 2015 – 2021

Table 12: North America Liposomal Doxorubicin Market , By Country, 2022 – 2032

Table 13: Latin America Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2015 – 2021

Table 14: Latin America Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2022 – 2032

Table 15: Latin America Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2015 – 2021

Table 16: Latin America Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2022 – 2032

Table 17: Latin America Liposomal Doxorubicin Market , By Country, 2015 – 2021

Table 18: Latin America Liposomal Doxorubicin Market , By Country, 2022 – 2032

Table 19: Europe Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2015 – 2021

Table 20: Europe Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2022 – 2032

Table 21: Europe Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2015 – 2021

Table 22: Europe Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2022 – 2032

Table 23: Europe Liposomal Doxorubicin Market , By Country, 2015 – 2021

Table 24: Europe Liposomal Doxorubicin Market , By Country, 2022 – 2032

Table 25: Asia Pacific Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2015 – 2021

Table 26: Asia Pacific Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2022 – 2032

Table 27: Asia Pacific Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2015 – 2021

Table 28: Asia Pacific Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2022 – 2032

Table 29: Asia Pacific Liposomal Doxorubicin Market , By Country, 2015 – 2021

Table 30: Asia Pacific Liposomal Doxorubicin Market , By Country, 2022 – 2032

Table 31: MEA Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2015 – 2021

Table 32: MEA Liposomal Doxorubicin Market Value (US$ Mn), By Product, 2022 – 2032

Table 33: MEA Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2015 – 2021

Table 34: MEA Liposomal Doxorubicin Market Value (US$ Mn), By Application , 2022 – 2032

Table 35: MEA Liposomal Doxorubicin Market , By Country, 2015 – 2021

Table 36: MEA Liposomal Doxorubicin Market , By Country, 2022 – 2032

Table 37: Global Liposomal Doxorubicin Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 38: Global Liposomal Doxorubicin Market Incremental $ Opportunity, By Application , 2022 – 2032

Table 39: Global Liposomal Doxorubicin Market Incremental $ Opportunity, By Region, 2022 – 2032

Table 40: North America Liposomal Doxorubicin Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 41: North America Liposomal Doxorubicin Market Incremental $ Opportunity, By Application , 2022 – 2032

Table 42: North America Liposomal Doxorubicin Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 43: Latin America Liposomal Doxorubicin Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 44: Latin America Liposomal Doxorubicin Market Incremental $ Opportunity, By Application , 2022 – 2032

Table 45: Latin America Liposomal Doxorubicin Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 46: Europe Liposomal Doxorubicin Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 47: Europe Liposomal Doxorubicin Market Incremental $ Opportunity, By Application , 2022 – 2032

Table 48: Europe Liposomal Doxorubicin Market Incremental $ Opportunity, By Country, 2022 - 2032

Table 49: Asia Pacific Liposomal Doxorubicin Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 50: Asia Pacific Liposomal Doxorubicin Market Incremental $ Opportunity, By Application , 2022 – 2032

Table 51: Asia Pacific Liposomal Doxorubicin Market Incremental $ Opportunity, By Country, 2022 – 2032

Table 52: MEA Liposomal Doxorubicin Market Incremental $ Opportunity, By Product, 2015 - 2021

Table 53: MEA Liposomal Doxorubicin Market Incremental $ Opportunity, By Application , 2022 – 2032

Table 54: MEA Liposomal Doxorubicin Market Incremental $ Opportunity, By Country, 2022 - 2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 1: Global Liposomal Doxorubicin Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 2: Global Liposomal Doxorubicin Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn

Figure 3: Global Liposomal Doxorubicin Market Share, By Product, 2022 & 2032

Figure 4: Global Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 5: Global Liposomal Doxorubicin Market Attractiveness Index, By Product – 2022-2032

Figure 6: Global Liposomal Doxorubicin Market Share, By Application , 2022 & 2032

Figure 7: Global Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Application – 2022-2032

Figure 8: Global Liposomal Doxorubicin Market Attractiveness Index, By Application – 2022-2032

Figure 9: Global Liposomal Doxorubicin Market Share, By Region, 2022 & 2032

Figure 10: Global Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Region – 2022-2032

Figure 11: Global Liposomal Doxorubicin Market Attractiveness Index, By Region – 2022-2032

Figure 12: North America Liposomal Doxorubicin Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 13: North America Liposomal Doxorubicin Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 14: North America Liposomal Doxorubicin Market Share, By Product, 2022 & 2032

Figure 15: North America Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 16: North America Liposomal Doxorubicin Market Attractiveness Index, By Product – 2022-2032

Figure 17: North America Liposomal Doxorubicin Market Share, By Application , 2022 & 2032

Figure 18: North America Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Application – 2022-2032

Figure 19: North America Liposomal Doxorubicin Market Attractiveness Index, By Application – 2022-2032

Figure 20: North America Liposomal Doxorubicin Market Share, By Country, 2022 & 2032

Figure 21: North America Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 22: North America Market Attractiveness Index, By Country – 2022-2032

Figure 23: Latin America Liposomal Doxorubicin Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 24: Latin America Liposomal Doxorubicin Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 25: Latin America Liposomal Doxorubicin Market Share, By Product, 2022 & 2032

Figure 26: Latin America Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 27: Latin America Liposomal Doxorubicin Market Attractiveness Index, By Product – 2022-2032

Figure 28: Latin America Liposomal Doxorubicin Market Share, By Application , 2022 & 2032

Figure 29: Latin America Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Application – 2022-2032

Figure 30: Latin America Liposomal Doxorubicin Market Attractiveness Index, By Application – 2022-2032

Figure 31: Latin America Liposomal Doxorubicin Market Share, By Country, 2022 & 2032

Figure 32: Latin America Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 33: Latin America Liposomal Doxorubicin Market Attractiveness Index, By Country – 2022-2032

Figure 34: Europe Liposomal Doxorubicin Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 35: Europe Liposomal Doxorubicin Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 36: Europe Liposomal Doxorubicin Market Share, By Product, 2022 & 2032

Figure 37: Europe Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 38: Europe Liposomal Doxorubicin Market Attractiveness Index, By Product – 2022-2032

Figure 39: Europe Liposomal Doxorubicin Market Share, By Application , 2022 & 2032

Figure 40: Europe Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Application – 2022-2032

Figure 41: Europe Liposomal Doxorubicin Market Attractiveness Index, By Application – 2022-2032

Figure 42: Europe Liposomal Doxorubicin Market Share, By Country, 2022 & 2032

Figure 43: Europe Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 44: Europe Liposomal Doxorubicin Market Attractiveness Index, By Country – 2022-2032

Figure 45: MEA Liposomal Doxorubicin Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 46: MEA Liposomal Doxorubicin Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 47: MEA Liposomal Doxorubicin Market Share, By Product, 2022 & 2032

Figure 48: MEA Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 49: MEA Liposomal Doxorubicin Market Attractiveness Index, By Product – 2022-2032

Figure 50: MEA Liposomal Doxorubicin Market Share, By Application , 2022 & 2032

Figure 51: MEA Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Application – 2022-2032

Figure 52: MEA Liposomal Doxorubicin Market Attractiveness Index, By Application – 2022-2032

Figure 53: MEA Liposomal Doxorubicin Market Share, By Country, 2022 & 2032

Figure 54: MEA Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 55: MEA Liposomal Doxorubicin Market Attractiveness Index, By Country – 2022-2032

Figure 56: Asia Pacific Liposomal Doxorubicin Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032

Figure 57: Asia Pacific Liposomal Doxorubicin Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn

Figure 58: Asia Pacific Liposomal Doxorubicin Market Share, By Product, 2022 & 2032

Figure 59: Asia Pacific Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Product – 2022-2032

Figure 60: Asia Pacific Liposomal Doxorubicin Market Attractiveness Index, By Product – 2022-2032

Figure 61: Asia Pacific Liposomal Doxorubicin Market Share, By Application , 2022 & 2032

Figure 62: Asia Pacific Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Application – 2022-2032

Figure 63: Asia Pacific Liposomal Doxorubicin Market Attractiveness Index, By Application – 2022-2032

Figure 64: Asia Pacific Liposomal Doxorubicin Market Share, By Country, 2022 & 2032

Figure 65: Asia Pacific Liposomal Doxorubicin Market Y-o-Y Growth Projections, By Country – 2022-2032

Figure 66: Asia Pacific Liposomal Doxorubicin Market Attractiveness Index, By Country – 2022-2032

Figure 67: US Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 68: US Liposomal Doxorubicin Market Share, By Product, 2021

Figure 69: US Liposomal Doxorubicin Market Share, By Application , 2021

Figure 70: Canada Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 71: Canada Liposomal Doxorubicin Market Share, By Product, 2021

Figure 72: Canada Liposomal Doxorubicin Market Share, By Application , 2021

Figure 73: Brazil Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 74: Brazil Liposomal Doxorubicin Market Share, By Product, 2021

Figure 75: Brazil Liposomal Doxorubicin Market Share, By Application , 2021

Figure 76: Mexico Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 77: Mexico Liposomal Doxorubicin Market Share, By Product, 2021

Figure 78: Mexico Liposomal Doxorubicin Market Share, By Application , 2021

Figure 79: Germany Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 80: Germany Liposomal Doxorubicin Market Share, By Product, 2021

Figure 81: Germany Liposomal Doxorubicin Market Share, By Application , 2021

Figure 82: U.K. Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 83: U.K. Liposomal Doxorubicin Market Share, By Product, 2021

Figure 84: U.K. Liposomal Doxorubicin Market Share, By Application , 2021

Figure 85: France Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 86: France Liposomal Doxorubicin Market Share, By Product, 2021

Figure 87: France Liposomal Doxorubicin Market Share, By Application , 2021

Figure 88: Italy Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 89: Italy Liposomal Doxorubicin Market Share, By Product, 2021

Figure 90: Italy Liposomal Doxorubicin Market Share, By Application , 2021

Figure 91: BENELUX Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 92: BENELUX Liposomal Doxorubicin Market Share, By Product, 2021

Figure 93: BENELUX Liposomal Doxorubicin Market Share, By Application , 2021

Figure 94: Nordic Countries Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 95: Nordic Countries Liposomal Doxorubicin Market Share, By Product, 2021

Figure 96: Nordic Countries Liposomal Doxorubicin Market Share, By Application , 2021

Figure 97: China Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 98: China Liposomal Doxorubicin Market Share, By Product, 2021

Figure 99: China Liposomal Doxorubicin Market Share, By Application , 2021

Figure 100: Japan Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 101: Japan Liposomal Doxorubicin Market Share, By Product, 2021

Figure 102: Japan Liposomal Doxorubicin Market Share, By Application , 2021

Figure 103: South Korea Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 104: South Korea Liposomal Doxorubicin Market Share, By Product, 2021

Figure 105: South Korea Liposomal Doxorubicin Market Share, By Application , 2021

Figure 106: GCC Countries Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 107: GCC Countries Liposomal Doxorubicin Market Share, By Product, 2021

Figure 108: GCC Countries Liposomal Doxorubicin Market Share, By Application , 2021

Figure 109: South Africa Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 110: South Africa Liposomal Doxorubicin Market Share, By Product, 2021

Figure 111: South Africa Liposomal Doxorubicin Market Share, By Application , 2021

Figure 112: Turkey Liposomal Doxorubicin Market Value (US$ Mn) and Forecast, 2022 - 2032

Figure 113: Turkey Liposomal Doxorubicin Market Share, By Product, 2021

Figure 114: Turkey Liposomal Doxorubicin Market Share, By Application , 2021

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Dental Microsurgery Market

Published : May 2022

Healthcare

Anatomic Pathology Market

Published : August 2020

Healthcare

Complement-targeted Therapeutics Market

Published : December 2019

Healthcare

Laboratory Information Systems (LIS) Market

Published : February 2022

Google translate

Liposomal Doxorubicin Market